Zota Health Care Shares Rated New 'Buy' At Nirmal Bang - Check Target Price, Potential Upside And More

1 week ago 9

ARTICLE AD BOX

Nirmal Bang initiates coverage on Zota Health with a 'Buy' rating citing strong growth trajectory.

12 Dec 2025, 10:45 AM IST i

12 Dec 2025, 10:45 AM IST

12 Dec 2025, 10:45 AM IST

<div class="paragraphs"><p>Davaindia contributes ~64% of Zota’s FY25 revenue and remains the company’s most important long-term growth driver.</p><p>(Photo: Zota website)</p></div>

Davaindia contributes ~64% of Zota’s FY25 revenue and remains the company’s most important long-term growth driver.

(Photo: Zota website)

Industry tailwinds—such as rising chronic disease burden, affordability pressures, and government push for generics—reinforce Zota’s positioning as a structural winner in India’s evolving pharmaceutical retail landscape.

To continue reading this story

You must be an existing Premium User

Already a Premium User?

Read Entire Article